Cerebrovascular Events and Use of NuvaRing
Autor: | Jessica E. Wilhoite, Amanda J Place |
---|---|
Rok vydání: | 2011 |
Předmět: |
medicine.medical_specialty
medicine.diagnostic_test business.industry Carotid arteries Pharmaceutical Science Magnetic resonance imaging Emergency department Transesophageal echocardiogram medicine.disease Surgery Venous thrombosis Occlusion medicine Single institution business Etonogestrel medicine.drug |
Zdroj: | Journal of Pharmacy Technology. 27:212-215 |
ISSN: | 1549-4810 8755-1225 |
DOI: | 10.1177/875512251102700504 |
Popis: | Objective: To report 2 cases, occurring within 1 month at a single institution, in which young women experienced a cerebrovascular event while using the hormonal contraceptive product NuvaRing (etonogestrel/ethinyl estradiol vaginal ring). Case Summary: The first patient presented to the emergency department (ED) with a 10-day history of right frontal headache. A computed tomography (CT) scan and magnetic resonance imaging showed evidence for right postcentral and cortical venous thrombosis. A hypercoagulable workup identified a heterozygous factor V Leiden mutation. The second patient presented to the ED with a same-day history of left frontotemporal headache extending into her left jaw and neck, numbness and clumsiness of right hand and right foot, and inability to make a comprehensible sentence. A CT angiogram showed occlusion of the internal and external carotid arteries. A hypercoagulable workup indicated no evidence of a thrombophilic disorder and a transesophageal echocardiogram indicated no cardioembolic source, resulting in a final diagnosis of a spontaneous carotid artery dissection. Both patients reported recent use of NuvaRing. The medication was discontinued during the hospital stay. Discussion: The use of hormonal agents for contraception carries a well-known risk of venous thrombosis; however, the impact this therapy has on the risk of arterial thrombosis and ischemic brain events is less understood. We found no previous reports of an ischemic brain event in association with NuvaRing use. The Naranjo probability scale indicated a possible relationship between the ischemic events and NuvaRing exposure in both patients. Conclusions: Risk factors should be evaluated appropriately prior to initiating any form of combined hormonal contraceptives, oral or vaginal, in young women. |
Databáze: | OpenAIRE |
Externí odkaz: |